Clinical Outcomes from Unselected Real-World Patients with Acute Myocardial Infarction Receiving Biodegradable Polymer Coated Sirolimus-Eluting Stents
DOI:
https://doi.org/10.12970/2311-052X.2013.01.02.5Keywords:
Acute myocardial infarction, Percutaneous Coronary Intervention, Sirolmus-eluting stent, biodegradable polymer.Abstract
Objectives: To investigate clinical outcomes of acute myocardial infarction population in a real-life setting when treated with Indolimus® biodegradable polymer coated sirolimus-eluting coronary stent.
Background: Drug-eluting stents in acute myocardial infarction are still feared for possible late and very late stent thrombosis. Newer antiproliferative drugs and more biodegradable polymers have shown promise in reducing further the rate of late stent thrombosis in patients with stable angina. However, limited data is available on the safety and efficacy of biodegradable polymer coated drug-eluting stent in acute myocardial infarction patients.
Methods: We studied patients undergoing cardiac catheterization with acute myocardial infarction (n=239) and without acute myocardial infarction (n=291) who had been implanted with Indolimus® sirolimus-eluting stents. The outcomes were reported for 1 and 6-months. The primary endpoint was the composite of major adverse cardiac events at 1 and 6-months after discharge from hospital. The secondary endpoint was stent thrombosis.
Results: A higher proportion of patients in the acute myocardial infarction group had renal insufficiency at screening (p=0.02), but there was a higher proportion of patients with a history of myocardial infarction (p<0.001), previous percutaneous coronary intervention (p=0.01) in the non- myocardial infarction group. The frequency of type B2/C lesions (p<0.001) and chronic total occlusion (p<0.001) was higher in the myocardial infarction group. There was no significant difference in parameters related to target vessel distribution and severity of disease. The six months follow-up was completed for 516 (97.4%) enrolled patients. The incidence of any major adverse cardiac events at 6-months was 2.1% and 4.2% for non-myocardial infarction and myocardial infarction population, respectively. There was no stent thrombosis up to 6-months in both groups.
Conclusions: In this all-comer, real-world Indolimus acute myocardial infarction study, major adverse cardiac events rates did not differ between acute myocardial infarction and non-acute myocardial infarction population. Six-month observation of acute myocardial infarction treatment using Indolimus® stent compared with non- acute myocardial infarction has no clinical disadvantage.
References
Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221-31. http://dx.doi.org/10.1056/NEJMoa032441
Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007; 356: 1030-9. http://dx.doi.org/10.1056/NEJMoa067484
Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007; 356: 1009-19. http://dx.doi.org/10.1056/NEJMoa067722
Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice. Lancet 2007; 369: 667-78. http://dx.doi.org/10.1016/S0140-6736(07)60314-6
Kotani J, Awata M, Nanto S, et al. Incomplete neointimal coverage of sirolimus-eluting stents. Angioscopic findings. J Am Coll Cardiol 2006; 47: 2108-11. http://dx.doi.org/10.1016/j.jacc.2005.11.092
Joner M, Nakazawa G, Finn AV, et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol 2008; 52: 333-42. http://dx.doi.org/10.1016/j.jacc.2008.04.030
Holmes DR Jr, Kereiakes DJ, Garg S, et al. Stent thrombosis. J Am Coll Cardiol 2010; 56: 1357-65. http://dx.doi.org/10.1016/j.jacc.2010.07.016
Cook S, Ladich E, Nakazawa G, et al. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation 2009; 120: 391-9. http://dx.doi.org/10.1161/CIRCULATIONAHA.109.854398
Nakazawa G, Finn AV, Joner M, et al. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study. Circulation 2008; 118: 1138-45. http://dx.doi.org/10.1161/CIRCULATIONAHA.107.762047
Finn AV, Nakazawa G, Kolodgie F, Virmani R. Drug eluting or bare metal stent for acute myocardial infarction: an issue of safety? Eur Heart J 2009; 30:1828-30. http://dx.doi.org/10.1093/eurheartj/ehp237
Nakazawa G. Stent thrombosis of drug eluting stent: pathological perspective. J Cardiol 2011; 58: 84-91. http://dx.doi.org/10.1016/j.jjcc.2011.07.004
Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007; 115: 2344-51. http://dx.doi.org/10.1161/CIRCULATIONAHA.106.685313
Guagliumi G, Sirbu V, Musumeci G, et al. Examination of the in vivo mechanisms of late drug-eluting stent thrombosis. J Am Coll Cardiol Intv 2012; 5: 12-20. http://dx.doi.org/10.1016/j.jcin.2011.09.018
Nakazawa G, Otsuka F, Nakano M, et al. The pathology of neoatherosclerosis in human coronary implants: bare-metal and drug-eluting stents. J Am Coll Cardiol 2011; 57: 1314-22. http://dx.doi.org/10.1016/j.jacc.2011.01.011
Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 2004; 109: 701-5. http://dx.doi.org/10.1161/01.CIR.0000116202.41966.D4
Nakazawa G, Finn AV, Vorpahl M, Ladich ER, Kolodgie FD, Virmani R. Coronary responses and differential mechanisms of late stent thrombosis attributed to first-generation sirolimus- and paclitaxel-eluting stents. J Am Coll Cardiol 2011; 57: 390-8. http://dx.doi.org/10.1016/j.jacc.2010.05.066
Lüscher TF, Steffel J, Eberli FR, et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 2007; 115: 1051-8. http://dx.doi.org/10.1161/CIRCULATIONAHA.106.675934
Finn AV, Nakazawa G, Joner M, et al. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol 2007; 27:1500-10. http://dx.doi.org/10.1161/ATVBAHA.107.144220
Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48: 193-202. http://dx.doi.org/10.1016/j.jacc.2006.03.042
Spaulding C, Henry P, Teiger E, et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 2006; 355: 1093-104. http://dx.doi.org/10.1056/NEJMoa062006
Laarman GJ, Suttorp MJ, Dirksen MT, et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 2006; 355: 1105-13. http://dx.doi.org/10.1056/NEJMoa062598
Kastrati A, Dibra A, Spaulding C, et al. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur Heart J 2007; 28: 2706-13. http://dx.doi.org/10.1093/eurheartj/ehm402
Brar SS, Leon MB, Stone GW, et al. Use of drug-eluting stents in acute myocardial infarction: a systematic review and meta-analysis. J Am Coll Cardiol 2009; 53: 1677-89. http://dx.doi.org/10.1016/j.jacc.2009.03.013
Mauri L, Silbaugh TS, Garg P, et al. Drug-eluting or bare-metal stents for acute myocardial infarction. N Engl J Med 2008; 359: 1330-42. http://dx.doi.org/10.1056/NEJMoa0801485
Spaulding C, Teiger E, Commeau P, et al. Four-year follow-up of TYPHOON (trial to assess the use of the CYPHer sirolimus-eluting coronary stent in acute myocardial infarction treated with BallOON angioplasty). JACC Cardiovasc Interv 2011; 4: 14-23. http://dx.doi.org/10.1016/j.jcin.2010.10.007
